Moolec Science (NASDAQ:MLEC – Get Free Report) is one of 493 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Moolec Science to related companies based on the strength of its valuation, risk, analyst recommendations, dividends, institutional ownership, profitability and earnings.
Profitability
This table compares Moolec Science and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Moolec Science | -129.97% | -93.88% | -33.37% |
Moolec Science Competitors | -7,194.89% | -103.05% | -26.50% |
Institutional & Insider Ownership
0.1% of Moolec Science shares are held by institutional investors. Comparatively, 32.8% of shares of all “Biotechnology” companies are held by institutional investors. 19.9% of Moolec Science shares are held by company insiders. Comparatively, 20.5% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Earnings & Valuation
This table compares Moolec Science and its competitors gross revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Moolec Science | $5.63 million | -$7.31 million | -4.50 |
Moolec Science Competitors | $1.60 billion | $49.77 million | 112.30 |
Moolec Science’s competitors have higher revenue and earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Moolec Science and its competitors, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Moolec Science | 0 | 0 | 1 | 0 | 3.00 |
Moolec Science Competitors | 966 | 2819 | 6942 | 111 | 2.57 |
Moolec Science presently has a consensus price target of $6.00, indicating a potential upside of 567.41%. As a group, “Biotechnology” companies have a potential upside of 25.26%. Given Moolec Science’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Moolec Science is more favorable than its competitors.
Summary
Moolec Science competitors beat Moolec Science on 8 of the 13 factors compared.
About Moolec Science
Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.
Receive News & Ratings for Moolec Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moolec Science and related companies with MarketBeat.com's FREE daily email newsletter.